Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
0.00%
)
US TECH 100
23,602.00
(
-0.82%
)
Dow Jones
46,225.15
(
0.00%
)
Brent Oil
109.07
(
2.33%
)
Bitcoin
69,315.89
(
-2.70%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 109449

Wednesday, 11/24/2010 12:54:12 PM

Wednesday, November 24, 2010 12:54:12 PM

Post# of 257257

Last month Roche said they are moving forward with an INFORM-SVR study (RG7227 with ritonavir boosting), which should start Q1/11. What's the point of Roche mentioning INFORM-SVR if in fact INFORM is completely dead?

Since then, Roche announced a major restructuring, which includes pruning some clinical programs. RG7227/INFORM is probably one of the programs being pruned, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now